CATAPLEXY
Clinical trials for CATAPLEXY explained in plain language.
Never miss a new study
Get alerted when new CATAPLEXY trials appear
Sign up with your email to follow new studies for CATAPLEXY, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New drug shows promise for reducing narcolepsy attacks over the long term
Symptom relief CompletedThis study looked at the long-term safety and effectiveness of a drug called AXS-12 for people with narcolepsy who also have sudden muscle weakness (cataplexy) and severe daytime sleepiness. 68 people who had already completed an earlier study took AXS-12 and were monitored for s…
Matched conditions: CATAPLEXY
Phase: PHASE3 • Sponsor: Axsome Therapeutics, Inc. • Aim: Symptom relief
Last updated Jun 15, 2026 18:57 UTC
-
New once-nightly drug could simplify narcolepsy treatment
Symptom relief CompletedThis study tested a new once-nightly medication (FT218) for people with narcolepsy who experience excessive daytime sleepiness and sudden muscle weakness (cataplexy). It included 184 participants, some already on a twice-nightly treatment and others new to this type of medicine. …
Matched conditions: CATAPLEXY
Phase: PHASE3 • Sponsor: Avadel • Aim: Symptom relief
Last updated Jun 11, 2026 12:10 UTC
-
New pill aims to tame Narcolepsy's sudden collapses and crushing fatigue
Symptom relief CompletedThis study tested an investigational drug called AXS-12 in 90 people with narcolepsy who experience cataplexy (sudden muscle weakness) and excessive daytime sleepiness. The goal was to see if the drug could safely reduce the number of cataplexy attacks and improve alertness compa…
Matched conditions: CATAPLEXY
Phase: PHASE3 • Sponsor: Axsome Therapeutics, Inc. • Aim: Symptom relief
Last updated Jun 10, 2026 13:27 UTC